Last reviewed · How we verify
ISIS-PTP1BRx
ISIS-PTP1BRx is a Antisense oligonucleotide (PTP1B inhibitor) Small molecule drug developed by Ionis Pharmaceuticals, Inc.. It is currently in Phase 2 development for Type 2 diabetes mellitus, Obesity.
ISIS-PTP1BRx is an antisense oligonucleotide that inhibits protein tyrosine phosphatase 1B (PTP1B) to improve insulin signaling and glucose metabolism.
ISIS-PTP1BRx is an antisense oligonucleotide that inhibits protein tyrosine phosphatase 1B (PTP1B) to improve insulin signaling and glucose metabolism. Used for Type 2 diabetes mellitus, Obesity.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ISIS-PTP1BRx |
|---|---|
| Sponsor | Ionis Pharmaceuticals, Inc. |
| Drug class | Antisense oligonucleotide (PTP1B inhibitor) |
| Target | PTP1B (Protein Tyrosine Phosphatase 1B) |
| Modality | Small molecule |
| Therapeutic area | Metabolic/Endocrinology |
| Phase | Phase 2 |
Mechanism of action
PTP1B is a negative regulator of insulin receptor signaling; by reducing PTP1B expression, the drug enhances insulin sensitivity and glucose uptake in target tissues. This mechanism is intended to improve glycemic control and metabolic parameters in metabolic diseases. The antisense approach allows selective reduction of the target protein without affecting other pathways.
Approved indications
- Type 2 diabetes mellitus
- Obesity
Common side effects
- Injection site reactions
- Liver enzyme elevation
- Platelet reduction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ISIS-PTP1BRx CI brief — competitive landscape report
- ISIS-PTP1BRx updates RSS · CI watch RSS
- Ionis Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about ISIS-PTP1BRx
What is ISIS-PTP1BRx?
How does ISIS-PTP1BRx work?
What is ISIS-PTP1BRx used for?
Who makes ISIS-PTP1BRx?
What drug class is ISIS-PTP1BRx in?
What development phase is ISIS-PTP1BRx in?
What are the side effects of ISIS-PTP1BRx?
What does ISIS-PTP1BRx target?
Related
- Drug class: All Antisense oligonucleotide (PTP1B inhibitor) drugs
- Target: All drugs targeting PTP1B (Protein Tyrosine Phosphatase 1B)
- Manufacturer: Ionis Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Metabolic/Endocrinology
- Indication: Drugs for Type 2 diabetes mellitus
- Indication: Drugs for Obesity
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing